You are here

Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting

Last updated on April 20, 2018

FOR MORE INFORMATION
Study Location
First People's Hospital of Fuyang City
Fuyang, Anhui, 236000 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypercholesterolemia Coronary Artery Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men and women aged ≥18 years;

- Cardiology patients who has been prescribed atorvastatin by physician's clinical
judgment under normal clinical care. These patients will include those with
established coronary heart disease, or having multiple risk factors and at risk for
cardiovascular disease, or primary hypercholesterolemia.

- Baseline laboratory reports prior to starting atorvastatin therapy can be tracked ,
including lipid measurement, liver function, and Creatine Kinase (CK) value. The date
of baseline reports should be within 1 month before taking atorvastatin or within 24h
after starting atorvastatin therapy.

- Evidence of a personally or his/her legally acceptable representative signed and dated
informed consent document indicating that the patient has been informed of all
pertinent aspects of the study and accept follow-up visit.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have regularly taken atorvastatin therapy more than 4 weeks before
enrollment

- Concomitant any other lipid-lower medication at baseline, or during the study
conduction on physician clinical judgement

NCT02565615
Pfizer
Recruiting
Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
Atorvastatin Effectiveness And Safety In Cardiology Patients In Real World Setting: A Registry Study In China
The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD?
Not Provided
Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
12 Weeks
Not Provided
Non-Probability Sample
Chinese cardiology patients
Coronary Artery Disease, Hypercholesterolemia, Hypertension
Other: No intervention
Because this is a non-interventional study, there is no intervention here.
Atorvastatin dose titration (single-arm)
Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
Intervention: Other: No intervention
Not Provided
 
Recruiting
10000
October 23, 2018
October 23, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women aged ?18 years;
  • Cardiology patients who has been prescribed atorvastatin by physician's clinical judgment under normal clinical care. These patients will include those with established coronary heart disease, or having multiple risk factors and at risk for cardiovascular disease, or primary hypercholesterolemia.
  • Baseline laboratory reports prior to starting atorvastatin therapy can be tracked , including lipid measurement, liver function, and Creatine Kinase (CK) value. The date of baseline reports should be within 1 month before taking atorvastatin or within 24h after starting atorvastatin therapy.
  • Evidence of a personally or his/her legally acceptable representative signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study and accept follow-up visit.

Exclusion Criteria:

  • Patients who have regularly taken atorvastatin therapy more than 4 weeks before enrollment
  • Concomitant any other lipid-lower medication at baseline, or during the study conduction on physician clinical judgement
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
China
 
 
NCT02565615
A2581197
No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now